LivaNova PLC $LIVN Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. lessened its position in LivaNova PLC (NASDAQ:LIVN) by 72.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,294 shares of the company’s stock after selling 73,871 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in LivaNova were worth $1,482,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of LIVN. GAMMA Investing LLC raised its position in LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock valued at $28,000 after buying an additional 407 shares during the period. State of Wyoming acquired a new stake in shares of LivaNova during the 2nd quarter valued at $31,000. EverSource Wealth Advisors LLC grew its holdings in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of LivaNova by 1,312.3% during the 2nd quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock valued at $46,000 after acquiring an additional 958 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of LivaNova in the first quarter worth $130,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN opened at $62.87 on Friday. The stock has a market capitalization of $3.43 billion, a price-to-earnings ratio of -15.72 and a beta of 1.02. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $65.57. The firm has a fifty day simple moving average of $58.30 and a 200 day simple moving average of $52.83. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LIVN. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of LivaNova in a report on Wednesday, September 3rd. Mizuho increased their target price on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a research report on Monday. Robert W. Baird set a $75.00 price objective on shares of LivaNova in a report on Tuesday, December 16th. Finally, The Goldman Sachs Group set a $55.00 price objective on shares of LivaNova and gave the stock a “neutral” rating in a research note on Wednesday, October 1st. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $65.63.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.